Connect, Share, Innovate — 120 seconds at the forefront of Alzheimer'sand neurodegenerative diseases
Date: 5th November 2026
Time: 3:00 PM – 6:30 PM (registration from 2:30 PM)
Venue: MultiplexDX, Science Park of Comenius University, Ilkovičova 8, Bratislava
Language: English
Capacity: 100 participants - limited seats
Field: Tackling Alzheimer's, related dementias and other neurodegenerative diseases through research, care, and innovation
Why join?
The first ADDIT-CE NeuroConnect Meetup (Brno, November 2025) brought together 22 pitch presenters and an afternoon of conversations that carried on long after the programme ended. For the second edition, the consortium moves to Bratislava - to the Science Park of Comenius University, home of MultiplexDX.
The format stays deliberately simple: short, sharp presentations followed by open networking. This year, investors will be part of the audience - so your 120 seconds reach not only research partners and clinicians, but also the people who fund what comes next.
What's new in 2026: the Science for Investors training workshop
Excellent research isn't enough on its own. To reach investors, companies or industry partners, it has to be clear what problem you solve, what solution you bring and who it creates value for.
That's why this year's meetup comes with an optional preparation step, organised by the ADDIT-CEand BridgeTTe projects together with JIC:
Workshop details and full programme → Workshop: Jak mluvit o svém výzkumu s investory.
How to sign up: Indicate your interest in our event registration form and we will forward your details directly to JIC, who will confirm your place by e-mail. Please express your interest by 7 September 2026.
What to expect on 5 November:
Programme
[Detailed programme will be published closer to the event.]
Present your solution in 120 seconds
Are you developing a new technology, service or research project related to Alzheimer's disease, related dementias or other neurodegenerative diseases? Do you provide care or support services for patients and families? Do you want potential partners, investors or healthcare providers to know about it?
This is your chance. Simply tick "I want to showcase atthe event" in the registration form. 20 slots are available - pitch topics by 16 October 2026. If you'd like to rehearse first, express your interest in the September workshop in the same form.
Who should attend?
About ADDIT-CE
ADDIT-CE - Alzheimer's Disease Diagnostics Innovation and Translation to Clinical Practice in Central Europe - connects research teams from CEITEC MU, Faculty of Science MU, Faculty of Medicine MU, FNUSA, the Biomedical Centre SAS and the Institute of Neuroimmunology SAS with the biotechnology companies BioVendor, MultiplexDX and Geneton. Its mission isto link the research and innovation ecosystems of the Brno and Bratislava regions, modernise Alzheimer's diagnostics and transfer new technologies into clinical practice.
This event has received funding from the European Union's Horizon Europe programme under Grant Agreement No. 101087124. Views and opinions expressed are however those of the author(s) only and do not necessarily reflect those of the European Union. Neither the European Union northe granting authority can be held responsible for them.
If you have any questions, contact us: events@multiplexdx.com
MultiplexDX is one of the most innovative biotech corporations, created to bring its revolutionary technologies to the market of personalized molecular diagnostics. The company has representation in both U.S. and European markets. The collaborators of MultiplexDX are from the world’s most prestigious scientific organizations including the National Cancer Institute, Rockefeller University, Albert Einstein University, Vanderbilt University, Cornell University, Queens University (Canada), Hebrew University of Jerusalem (Israel), and the Max Delbrück Center for Molecular Medicine (Germany).
MultiplexDX IP-based and innovative platform merges histopathology methods, biomarker quantification, visualization and gene expression with a single-cell resolution by combining MDX proprietary visual and sequencing technologies into one diagnostic test. This cross-validation approach eliminates diagnostic errors and creates 100% precise cancer profiling for each patient which allows clinicians to suggest specific, personalized cancer treatment.
Find out more about MultiplexDX on Corporate website, Facebook, LinkedIn, Twitter
